DNLI — Denali Therapeutics Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1714899 ·
Last close
$20.39
Market Cap
$3.26B
52W High
$27.30
52W Low
$13.28
ADV30
1,415,917
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 3,604,000 | 3,511,000 | -130,541,000 | -127,553,000 | 1,157,955,000 | 201,530,000 | 322,777,000 |
| Mar 2026 | 0 | — | -137,357,000 | -128,447,000 | 1,266,023,000 | 387,626,000 | 339,925,000 |
| Dec 2025 | 0 | — | -137,365,000 | -128,549,000 | 1,144,854,000 | 205,326,000 | 131,093,000 |
| Sep 2025 | 0 | — | -137,434,000 | -126,902,000 | 1,055,621,000 | 90,963,000 | 129,424,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-434,040,000
Investing CF
$68,980,000
Financing CF
$425,383,000
CapEx
$-37,873,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.84
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,307,524,000
Inventory
$4,139,000
Receivables
$3,927,000
ST Investments
$508,941,000
EBIT TTM
$-542,697,000
Pretax Income TTM
$-511,349,000
Interest Exp TTM
—
Analysts
16
Yahoo Snapshot (yfinance, live)
Total Revenue
$3,604,000
EBITDA
$-526,057,984
Free Cash Flow
$-268,527,872
Enterprise Value
$2,698,396,672
Total Cash
$710,470,976
Total Debt
$37,686,000
Shares Out
159,847,403
Trailing EPS
$-2.84
Book Value
$5.23
ROE
-54.9%
ROA
-29.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -555,342,000 | -512,540,000 | 1,144,854,000 | 131,093,000 | 1,013,761,000 | -412,600,000 |
| Dec 2024 | 0 | -501,878,000 | -422,773,000 | 1,374,180,000 | 144,496,000 | 1,229,684,000 | -347,694,000 |
| Dec 2023 | 330,531,000 | -196,699,000 | -145,224,000 | 1,153,917,000 | 122,963,000 | 1,030,954,000 | -357,991,000 |
| Dec 2022 | 108,463,000 | -340,744,000 | -325,991,000 | 1,460,242,000 | 417,812,000 | 1,042,430,000 | -244,716,000 |
TTM Snapshot
Revenues TTM
$4,826,000
NetIncome TTM
$-442,814,000
OpCashFlow TTM
$0
Assets (Latest)
$1,144,854,000
Forward EPS
$-2.42
Max Pain — expiry 2026-12-18
max pain strike: $15.00 · spot: $20.39 · call oi: 610 · put oi: 1,095
Expected Move to 2026-12-18:
±$5.45
(26.73%) —
implied range
$14.94 –
$25.84
· ATM straddle on $20.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TARS | Tarsus Pharmaceuticals, Inc. | $3.54B | $75.69 | — |
| RLAY | Relay Therapeutics, Inc. | $3.83B | $17.47 | — |
| BEAM | Beam Therapeutics Inc. | $2.51B | $24.27 | — |
| MEOBF | MESOBLAST LTD | $2.47B | $1.90 | — |
| ADPT | Adaptive Biotechnologies Corp | $4.70B | $29.43 | — |
News headlines (Yahoo Finance, 1h cache)
Denali Therapeutics (DNLI) Q2 2026 Earnings Call Transcript
2026-08-13 22:32 · Yahoo
Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026
2026-07-27 20:01 · Yahoo
Denali Therapeutics to Give Opening Plenary Address at Alzheimer’s Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic Therapies Across Blood-Brain Barr
2026-07-09 20:01 · Yahoo
Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million
2026-06-18 12:00 · Yahoo
Denali Therapeutics Inc. Q2 2026 Earnings Call Summary
2026-08-07 12:30 · Yahoo
Will Recent Setbacks Impact Growth Prospects of DNLI Stock?
2026-07-15 17:02 · Yahoo
Denali to Sell Priority Review Voucher for $195M Cash Boost
2026-06-19 12:40 · Yahoo
DNLI Stock Gains 33.1% in Three Months: Buy, Sell or Hold the Stock?
2026-08-20 16:20 · Yahoo
Should You Buy, Sell or Hold Biogen Stock After a 9% Rise in a Month?
2026-08-20 14:12 · Yahoo
DNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch Momentum
2026-08-07 18:31 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.